JP5886194B2 - インフルエンザ感染の診断および／または処置のための組成物および方法 - Google Patents

インフルエンザ感染の診断および／または処置のための組成物および方法 Download PDF

Info

Publication number
JP5886194B2
JP5886194B2 JP2012517927A JP2012517927A JP5886194B2 JP 5886194 B2 JP5886194 B2 JP 5886194B2 JP 2012517927 A JP2012517927 A JP 2012517927A JP 2012517927 A JP2012517927 A JP 2012517927A JP 5886194 B2 JP5886194 B2 JP 5886194B2
Authority
JP
Japan
Prior art keywords
polypeptide
fold
binding
topology
umbrella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012517927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532117A5 (enExample
JP2012532117A (ja
Inventor
アキラ ジャヤラマン，
アキラ ジャヤラマン，
カーティック ビスワナサン，
カーティック ビスワナサン，
ラウル ラマン，
ラウル ラマン，
ザッカリー エイチ． シュリバー，
ザッカリー エイチ． シュリバー，
サシセカラン，　ラム
ラム サシセカラン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2012532117A publication Critical patent/JP2012532117A/ja
Publication of JP2012532117A5 publication Critical patent/JP2012532117A5/ja
Application granted granted Critical
Publication of JP5886194B2 publication Critical patent/JP5886194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012517927A 2009-07-02 2010-07-02 インフルエンザ感染の診断および／または処置のための組成物および方法 Active JP5886194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22288909P 2009-07-02 2009-07-02
US61/222,889 2009-07-02
PCT/US2010/040978 WO2011003100A2 (en) 2009-07-02 2010-07-02 Compositions and methods for diagnosing and/or treating influenza infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015224253A Division JP2016028107A (ja) 2009-07-02 2015-11-16 インフルエンザ感染の診断および／または処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012532117A JP2012532117A (ja) 2012-12-13
JP2012532117A5 JP2012532117A5 (enExample) 2013-08-15
JP5886194B2 true JP5886194B2 (ja) 2016-03-16

Family

ID=43411785

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012517927A Active JP5886194B2 (ja) 2009-07-02 2010-07-02 インフルエンザ感染の診断および／または処置のための組成物および方法
JP2015224253A Withdrawn JP2016028107A (ja) 2009-07-02 2015-11-16 インフルエンザ感染の診断および／または処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015224253A Withdrawn JP2016028107A (ja) 2009-07-02 2015-11-16 インフルエンザ感染の診断および／または処置のための組成物および方法

Country Status (7)

Country Link
US (2) US9278998B2 (enExample)
EP (1) EP2448596B1 (enExample)
JP (2) JP5886194B2 (enExample)
AU (1) AU2010266129B2 (enExample)
CA (1) CA2766899C (enExample)
ES (1) ES2566361T3 (enExample)
WO (1) WO2011003100A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
WO2011094445A1 (en) * 2010-01-27 2011-08-04 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
AU2011305371B2 (en) 2010-09-21 2015-05-21 Massachusetts Institute Of Technology Human-adapted HA polypeptides, vaccines, and influenza treatment
AU2011312178B2 (en) 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP2016517414A (ja) 2013-03-15 2016-06-16 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア インフルエンザ核酸分子及びそれから作製したワクチン
US10301359B2 (en) * 2013-04-30 2019-05-28 Massachusetts Institute Of Technology Human adaptation of H3 influenza
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US11781112B2 (en) 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2021258916A1 (en) * 2020-04-22 2022-11-24 Aramis Biotechnologies Inc. Suprastructure comprising modified influenza hemagglutinin with reduced interaction with sialic acid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4692411A (en) 1983-09-06 1987-09-08 Ghose Rabindra N Separation of specific biological cells by a biochemical filter
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US6085349A (en) * 1997-08-27 2000-07-04 Qualcomm Incorporated Method for selecting cyclic redundancy check polynomials for linear coded systems
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2006108226A1 (en) 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
SG169996A1 (en) * 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
US20100143393A1 (en) 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20090081193A1 (en) * 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2052340A4 (en) * 2006-08-14 2010-11-17 Massachusetts Inst Technology SYSTEM FOR EXPLORING DATA ON GLYCANES
AU2007304883B2 (en) 2006-10-04 2013-09-05 The University Of Queensland VLP based vaccine delivery system
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
PT2540312E (pt) 2007-07-19 2015-08-31 Novavax Inc Vlps quiméricas de gripe aviária
JP2011508785A (ja) * 2008-01-03 2011-03-17 マサチューセッツ インスティテュート オブ テクノロジー デコイインフルエンザ処置
DK2318530T3 (en) 2008-07-18 2016-10-03 Medicago Inc Ny epitope to immunization against influenza
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection

Also Published As

Publication number Publication date
AU2010266129B2 (en) 2016-04-14
US20110033490A1 (en) 2011-02-10
AU2010266129A1 (en) 2012-02-02
US9709567B2 (en) 2017-07-18
WO2011003100A3 (en) 2011-02-24
US20160266117A1 (en) 2016-09-15
ES2566361T3 (es) 2016-04-12
CA2766899A1 (en) 2011-01-06
WO2011003100A2 (en) 2011-01-06
EP2448596B1 (en) 2016-01-06
EP2448596A2 (en) 2012-05-09
CA2766899C (en) 2021-05-04
JP2012532117A (ja) 2012-12-13
JP2016028107A (ja) 2016-02-25
EP2448596A4 (en) 2013-02-20
US9278998B2 (en) 2016-03-08
WO2011003100A4 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
US9709567B2 (en) Compositions and methods for diagnosing and/or treating influenza infection
US20190142931A1 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
US9745352B2 (en) Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
JP6518597B2 (ja) Ｈ５インフルエンザのヒトへの適応
US10526375B2 (en) Human Adaptation of H7 HA
HK1218923B (en) Human adaptation of h5 influenza
HK1215257B (en) Human adaptation of h5 influenza
BR112015018503B1 (pt) Polipeptídeo hemaglutinina (ha) h5, composição de vacina, método para fornecer uma vacina e kit de diagnóstico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160210

R150 Certificate of patent or registration of utility model

Ref document number: 5886194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250